Table 3.

Overview of Evidence for Treatment-Specific Baseline Investigations and Primary Prevention of Cardiotoxicity Events

Cancer Therapy Class	Conventional Cardiovascular Risk Factors	Imaging	NT-proBNP	cTn	HFA-ICOS	Primary Prevention
Anthracyclines	++	High/ medium risk: LVEF ++	+/-	+/-	O	Dose reduction: ++
		Low risk: O				Liposomal doxorubicin: ++
		GLS ++				Dexrazoxane: +
						Beta-blockers: +/-
						ACEI/A2RB: +/-
						Statins: +/-
HER2-targeted therapies	++	++	+/-	+/-	+	Beta-blockers: +/-
						ACEI/A2RB: +/-
Fluoropyrimidines	+/-	O	O	O	Not applicable	Nitrates/CCB: +
BRAF/MEK inhibitors	++	O	O	O	X	O
Androgen-deprivation therapy	++	O	O	O	Not applicable	Statins: +
Immune checkpoint inhibitors	Myocarditis: +/-	O	O	+	Not applicable	O
	Coronary events: ++	O	O	O	Not applicable	Statins: +
BCR:ABL tyrosine kinase inhibitors	++	O	O	O	O	O
Multiple myeloma therapies	++	O	PI: +	O	O	PI—high risk: DOAC
						PI—low risk: aspirin, LMWH
VEGFi	++	O	O	O	O	O
CAR-T cell therapies	++	++	+	O	Not applicable	O
Radiation therapy	++	O	O	O	Not applicable	Dose reduction: ++
Hematopoietic stem cell transplantation	++	O	O	O	Not applicable	O

Multiple studies with consensus results supporting effect (++), single study with evidence of effect (+), evidence differs between studies (+/-), evidence shows no effect (X), no evidence available (0), and not applicable (no risk calculator).

A2RB = angiotensin 2 receptor blocker; ACEI = angiotensin-converting enzyme inhibitor; CCB = calcium-channel blocker; cTn = cardiac troponin; DOAC = direct oral anticoagulant; HFA-ICOS = Heart Failure Association–International Cardio-Oncology Society; LMWH = low molecular weight heparin; MEK = mitogen-activated protein/extracellular signal-regulated/kinase; PI = proteosome inhibitor; other abbreviations as in Tables 1 and 2.